Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $6.4 million.

  • Seres Therapeutics' Accumulated Expenses fell 6397.61% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 6397.61%. This contributed to the annual value of $10.7 million for FY2024, which is 5237.9% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Accumulated Expenses is $6.4 million, which was down 6397.61% from $5.8 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Accumulated Expenses peaked at $86.4 million during Q2 2024, and registered a low of $5.8 million during Q2 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $45.1 million (2021), whereas its average is $38.8 million.
  • Per our database at Business Quant, Seres Therapeutics' Accumulated Expenses skyrocketed by 33205.51% in 2021 and then crashed by 9327.32% in 2025.
  • Over the past 5 years, Seres Therapeutics' Accumulated Expenses (Quarter) stood at $45.1 million in 2021, then surged by 32.7% to $59.8 million in 2022, then plummeted by 62.38% to $22.5 million in 2023, then tumbled by 52.38% to $10.7 million in 2024, then tumbled by 40.46% to $6.4 million in 2025.
  • Its Accumulated Expenses was $6.4 million in Q3 2025, compared to $5.8 million in Q2 2025 and $6.2 million in Q1 2025.